aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
NuvOx Pharma, founded in Tucson, Arizona, is a pharmaceutical company dedicated to developing oxygen-delivering drugs aimed at reversing hypoxia. The company's core mission is to address the lack of oxygen in the body's cells, which is a critical factor in numerous fatal diseases. NuvOx's platform involves intravenous drugs that travel through the bloodstream to the lungs to pick up oxygen and deliver it to hypoxic tissues. Their primary focus areas include treatments for stroke, oncology, and sickle cell crisis, with several drugs in Phase II and Phase Ib trials.
Notable affiliated individuals and investors include experts in medical research and pharmaceutical development, although specific names are not provided. NuvOx Pharma has achieved significant milestones, such as advancing their drug candidates to Phase II and Phase Ib clinical trials. Their innovative approach to treating hypoxia has the potential to impact various medical fields significantly, offering new hope for patients suffering from conditions like stroke, cancer, and sickle cell disease.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was NuvOx Pharma founded?
NuvOx Pharma was founded in 2008.
Where is NuvOx Pharma's headquarters located?
NuvOx Pharma's headquarters is located in Tucson, AZ, US.
How many employees does NuvOx Pharma have?
NuvOx Pharma has 6 employees as of Feb 4, 2024.
How much has NuvOx Pharma raised to-date?
As of July 05, 2023, NuvOx Pharma has raised a total of $19M (USD) since Apr 26, 2023.
Add Comparison
Total Raised to Date
$19M
USD
Last Update Apr 26, 2023
Total Employees Over Time
6
As of Feb 2024
NuvOx Pharma Address
1635 E. 18th Street
Tucson,
Arizona
85719
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts